Terns Pharmaceuticals reported early clinical data showing its oral targeted agent TERN‑701 produced high major molecular response rates in heavily pretreated chronic myeloid leukemia (CML) patients, prompting comparisons to Novartis’ Scemblix. Company statements and STAT summaries highlighted a 64% major molecular response at 24 weeks in an evaluable cohort and suggested the drug could 'raise the bar' for next‑generation CML therapies. Presentations at the American Society of Hematology and company releases stressed that results are preliminary but notable given the patients’ prior treatment history. Terns indicated plans to advance development and explore earlier‑line use if confirmatory data hold.